Novartis AG Form 6-K Summary: First Half 2009 Results
Business Context and Reporting Period
This Form 6-K, dated July 16, 2009, reports the unaudited financial results for Novartis AG for the first half (H1) and second quarter (Q2) of 2009. The company operates globally with a diversified portfolio including Pharmaceuticals, Vaccines and Diagnostics, Sandoz (generics), and Consumer Health. The reporting period highlights strong operational performance driven by pharmaceutical innovation, though reported results were negatively impacted by a stronger US dollar and financing costs related to the Alcon acquisition.
Key Financial Metrics
| Metric | H1 2009 (USD) | H1 2008 (USD) | Change (USD) | Change (Local Currency) |
|---|---|---|---|---|
| Net Sales | $20.3 billion | $20.6 billion | -2% | +8% |
| Operating Income | $4.7 billion | $4.9 billion | -5% | +11% (adjusted) |
| Net Income | $4.0 billion | $4.6 billion | -12% | N/A |
| Basic EPS | $1.76 | $2.01 | -12% | N/A |
| Free Cash Flow (before dividends) | $3.4 billion | $2.6 billion | +33% | N/A |
| Net Debt | $2.1 billion | $1.2 billion (Dec 2008) | Increased | N/A |
Q2 2009 Specifics: Net sales were $10.5 billion (-2% USD, +8% local currency). Operating income was $2.4 billion (-4% USD). Net income was $2.0 billion (-10% USD). Basic EPS was $0.90.
Material Changes vs. Prior Period
- Currency Impact: A stronger US dollar negatively impacted reported sales by approximately 10 percentage points. Underlying local currency growth was robust at 8% for the group and 12% for Pharmaceuticals.
- Pharmaceuticals Growth: The division grew 12% in local currencies, driven by new products (Lucentis, Exforge, Exjade, Exelon Patch, Reclast/Aclasta, Tasigna, Tekturna/Rasilez, Galvus) which contributed $2.0 billion in sales (15% of division sales).
- Profitability Pressures: Net income declined 12% due to currency effects, higher financing costs from the Alcon stake, and lower financial income. Operating income fell 5% in USD terms but rose 11% when adjusted for currency and exceptional items.
- Debt Structure: Net debt increased to $2.1 billion from $1.2 billion at year-end 2008, reflecting the issuance of a $5 billion USD bond and a €1.5 billion Euro bond to fund operations and the Alcon investment.
- Divisional Performance: Vaccines and Diagnostics sales declined 18% (USD) due to the absence of H5N1 pandemic vaccine sales compared to the prior year. Sandoz grew 4% in local currencies despite US price erosion.
Guidance, Outlook, and Risks
- Outlook: Management reaffirms expectations for strong underlying momentum in 2009. Group net sales are expected to grow at a mid-single-digit rate in local currencies. Pharmaceuticals net sales are expected to expand at a minimum high-single-digit rate in local currencies.
- Earnings Expectation: Underlying growth in operating and net income is expected to reach record levels in constant currencies, though reported results may be offset by currency-related losses.
- R&D Pipeline: Key developments include the US launch of Afinitor (anti-cancer), US approval of Ilaris (biologic), and the start of clinical trials for an H1N1 pandemic flu vaccine in July 2009.
- Productivity: The "Forward" initiative has achieved cumulative cost savings of $1.7 billion, exceeding the 2010 goal 18 months ahead of schedule.
- Risks and Contingencies:
- Legal Proceedings: Ongoing investigations regarding off-label promotion of Trileptal and TOBI; litigation regarding Zometa/Aredia (osteonecrosis of the jaw) and Zelnorm (cardiovascular injuries); and patent litigation with Johnson & Johnson regarding contact lenses.
- Regulatory: FDA inspection anticipated for the Sandoz Wilson manufacturing site in Q3 2009.
- Market Conditions: Uncertainty regarding the global financial crisis and exchange rates.
Investor Verification Checklist
- Verify the impact of currency fluctuations on reported vs. underlying growth metrics.
- Monitor the status of the FDA inspection at the Sandoz Wilson manufacturing site and potential impact on US sales.
- Track the progress of the H1N1 vaccine commercialization and contract fulfillment (US government contracts totaling $979 million).
- Review the timeline and regulatory status for key pipeline products: Afinitor (EU approval), Ilaris (global approvals), and FTY720 (MS therapy).
- Assess the financial impact of the Alcon acquisition financing costs and the potential for the second-step acquisition of the remaining Alcon stake.
- Monitor the outcome of major litigation cases, specifically Zometa/Aredia and Zelnorm, for potential liability exposure.